Document Type : Research Paper


1 Hitopathology Resident, Basrah Teaching Hospital, Basrah, Iraq

2 Professor of pathology. College of Medicine. University of Basrah.

3 Department of Pathology, faculty of Medicine, University of Basrah, Iraq.)

4 Lecturer،Southern Technical University, College of Medical Lab Technologies


Papillary thyroid carcinoma is the most common endocrine and thyroid malignancy. The (BRAF V600E) mutation is the most common mutation in papillary thyroid cancer (PTC). The mutation is detected in about (60%) of the cases. Patients with BRAF mutation have been linked to aggressive clinical behavior, high recurrence rate, metastasis, and failure of treatment.


1.Limaiem F, Rehman A, Anastasopoulou C. Papillary Thyroid Carcinoma. StatPearls Publishing; 2023.
2.LiVolsi VA. Papillary thyroid carcinoma: an update. Modern Pathology. 2011;24:S1–9. doi: 10.1038/modpathol.2010.129.
3.Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, et al. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 Apr;27(4):481–3. Doi: 10.1089/thy.2016.0628.
4.Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, et al. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. J Clin Endocrinol Metab. 2016 Jan;101(1):264–74. Doi: 10.1210/jc.2015-2917.
5.Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF Mutation in Papillary Thyroid Carcinoma. JNCI Journal of the National Cancer Institute. 2003 Apr 16;95(8):625–7. Doi: 10.1093/jnci/95.8.625.
6.Tang KT, Lee CH. BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications. Journal of the Chinese Medical Association. 2010 Mar;73(3):113–28. Doi: 10.1016/S1726-4901(10)70025-3.
7.Xing M. BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications. Endocr Rev. 2007 Dec 1;28(7):742–62.doi: 10.1210/er.2007-0007
8.Ma X, Xia C, Liu H, Zhu W. Primary thyroid spindle cell tumors: spindle cell variant of papillary thyroid carcinoma? Int J Clin Exp Pathol. 2015;8(10):13528–31.
9.Andrew JC. Stains & CD markers BRAF V600E [Internet]. 2022 [cited 2023 Oct 28]. Available from:
10.Kim WY, Kim H, Hwang TS, Oh SY. Comparison Between Real-Time PCR and Pyrosequencing for Detection of BRAF V600E Mutation in Thyroid Fine-Needle Aspirates. Applied Immunohistochemistry & Molecular Morphology. 2017 May;25(5):358–65.doi: 10.1097/PAI.0000000000000308
11.Martinuzzi C, Pastorino L, Andreotti V, Garuti A, Minuto M, Fiocca R, et al. A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer. Endocrine. 2016 Sep 22;53(3):672–80. Doi: 10.1007/s12020-015-0720-9
12.Szymonek M, Kowalik A, Kopczyński J, Gąsior-Perczak D, Pałyga I, Walczyk A, et al. Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma. Oncotarget. 2017 Sep 26;8(43):74897–909. doi: 10.18632/oncotarget.20451
13.Ban JM. Detection of Pan Braf in Thyroid Tumors in Iraqi Patients. IRAQI JOURNAL OF  SCIENCE. 2017 Oct 30;58(4A). DOI:
14.Al-Brahim N, Asa SL. Papillary Thyroid Carcinoma: An Overview. Arch Pathol Lab Med. 2006 Jul 1;130(7):1057–62. Doi: 10.5858/2006-130-1057-PTCAO
15.Burgess JR, Tucker P. Incidence Trends for Papillary Thyroid Carcinoma and Their Correlation with Thyroid Surgery and Thyroid Fine-Needle Aspirate Cytology. Thyroid. 2006 Jan;16(1):47–53.
16.John R. Goldblum, Laura W. Lamps, Jesse K. McKenney. Thyroid gland. In: Rosai and Ackerman’s Surgical Pathology . 11th ed. Elsevier; 2018. p. 297–309.
17.McKelvie PA, Chan F, Yu Y, Waring P, Gresshoff I, Farrell S, et al. The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology. 2013 Dec;45(7):637–44. Doi: 10.1097/PAT.0000000000000008
18.Wahid MHA, Almudhafar RH. Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features. J Med Life. 2022 Apr;15(4):520–5. Doi: 10.25122/jml-2021-0415
19.Parker KG, White MG, Cipriani NA. Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis. Head Neck Pathol. 2020 Dec 1;14(4):1067–79. Doi: 10.1007/s12105-020-01166-8.
20.Lung J, Hung MS, Lin YC, Jiang YY, Fang YH, Lu MS, et al. A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening. Sci Rep. 2020 Oct 9;10(1):16943. Doi: 10.1038/s41598-020-72809-7.
21.Teri A. Longacre, Joel K. Greenson, Jason LH, Victor E. Reuter. Pathology of thyroid and parathyroid. In: Mills and Sternberg’s Diagnostic Surgical Pathology. Wolters Kluwer Health; 2021. p. 1360–89.
22.Jones J, Gaillard F. Papillary thyroid cancer. In:; 2008. DOI:
23.Paja Fano M, Ugalde Olano A, Fuertes Thomas E, Oleaga Alday A. Detección inmunohistoquímica de la mutación BRAF V600E en el carcinoma papilar de tiroides. Evaluación frente a la reacción en cadena de la polimerasa en tiempo real. Endocrinol Diabetes Nutr. 2017 Feb;64(2):75–81.